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TRIM5α is a potent inhibitor of infection by diverse retroviruses and is encoded by one of a large family of TRIM genes. We found that several
TRIM motifs among a panel of selected human TRIM proteins (TRIM1, 5, 6, 18, 19, 21 22, 34) could inhibit infection when artificially targeted to
an incoming HIV-1 capsid. Conversely, when ectopically expressed as authentic full-length proteins, most lacked activity against a panel of
retroviruses. The exceptions were TRIM1, TRIM5 and TRIM34 proteins. Weak but specific inhibition of HIV-2/SIVMAC and EIAV by TRIM34
was noted, and human TRIM5α modestly, but specifically, inhibited an HIV-1 strain carrying a mutation in the cyclophilin binding loop (G89V).
Restriction activity observed in ectopic expression assays was sometimes not detectable in corresponding RNAi-based knockdown experiments.
However, endogenous owl monkey TRIMCyp potently inhibited an SIVAGM strain. Overall, sporadic examples of intrinsic antiretroviral activity
exist in this panel of TRIM proteins.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV-1; SIV; MLV; TRIM5; TRIM genes; Retrovirus; Intrinsic immunityIntroduction
Mammalian evolution has resulted in at least three
independent acquisitions of genes whose primary role appears
to be an intrinsic defense against retroviral infection (Best et al.,
1996; Bieniasz, 2004; Goff, 2004; Sheehy et al., 2002; Stremlau
et al., 2004). One group of genes, exemplified by APOBEC3G,
act primarily by deaminating cytidines in nascent retroviral
DNA (Bishop et al., 2004; Harris et al., 2003; Lecossier et al.,
2003; Liddament et al., 2004; Mangeat et al., 2003; Wiegand et
al., 2004; Yu et al., 2004; Zhang et al., 2003; Zheng et al., 2004),
while two others, Fv1 and tripartite motif-5 (TRIM5), target
incoming retroviral capsids to block infection by as yet poorly
defined mechanisms that may involve accelerated disassembly
(Kozak and Chakraborti, 1996; Sebastian and Luban, 2005;
Stremlau et al., 2004, 2006). The APOBEC3 locus appears to
have been under evolutionary pressure during mammalian
speciation (Sawyer et al., 2004). Indeed, while mice have only
one APOBEC3 gene, humans have no less than seven, that have⁎ Corresponding author. Fax: +1 212 725 1126.
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and exhibit varying levels of activity against numerous
retroviruses (Bishop et al., 2004; Doehle et al., 2005; Liddament
et al., 2004; Wiegand et al., 2004; Yu et al., 2004; Zheng et al.,
2004). Conversely, Fv1 has a rather different evolutionary
history and is apparently a remnant of an ancient endogenous
retrovirus (Best et al., 1996). It exists as a single gene, is unique
to the mouse, and specifically inhibits murine leukemia viruses
(MLV) (Baumann et al., 2004; Hatziioannou et al., 2004a).
Indeed, divergence in Fv1 and MLV capsid sequences is a major
determinant of the sensitivity of various mouse strains to
infection by various MLV strains (Bock et al., 2000; Kozak and
Chakraborti, 1996; Lassaux et al., 2005; Qi et al., 1998; Stevens
et al., 2004).
While Fv1 does not appear to target any retrovirus other than
MLV that has been tested thus far (Baumann et al., 2004;
Hatziioannou et al., 2004a), a similar type of intrinsic defense
encoded by the mammalian (TRIM5) gene has far broader
antiretroviral potential. Indeed, the TRIM5α protein is capable
of targeting a variety of widely divergent retroviral capsids
(Hatziioannou et al., 2004a,b; Keckesova et al., 2004; Perron et
al., 2004; Saenz et al., 2005; Yap et al., 2004). The extent to
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yet been fully documented, but all primates that have been
examined have a TRIM5 gene, while mice appear to lack a close
relative (Song et al., 2005b). Interestingly, TRIM5 is one
member of a family of dozens of genes that share a similar
architecture (Reymond et al., 2001). Indeed, TRIM5 itself exists
as part of a small cluster of closely related TRIM genes on
human chromosome 11 (Reymond et al., 2001).
Each TRIM gene encodes a protein with an amino terminal
tripartite motif, comprised of a RING domain, one or two
additional zinc binding or ‘B-box’ domains, and a coiled-coil
domain. The TRIM domain can be linked to one of a number of
C-terminal domains, and sometimes a single TRIM gene can
encode several variant proteins with different C-terminal
domains (Reymond et al., 2001). The TRIM5α protein contains
a C-terminal SPRY domain, which is related to domains found
in other proteins of diverse organization and function, as well as
in several other members of the TRIM protein family.
Functional dissection of the TRIM5α protein has revealed
that (1) the amino terminal RING domain is important for potent
inhibition of retrovirus infection but is not absolutely required,
(2) the B-box domain is required for inhibition, (3) the central
coiled-coil is necessary and sufficient for TRIM5 multimeriza-
tion, and (4) the C-terminal SPRY domain likely binds to
incoming capsids and is the principle determinant of specificity,
i.e., it determines which retroviruses are inhibited by a given
TRIM5α variant (Javanbakht et al., 2005; Nakayama et al.,
2005; Perez-Caballero et al., 2005a,b; Stremlau et al., 2005,
2006; Yap et al., 2005; Sawyer et al., 2005). Remarkably, a
retrotransposition event in Owl monkeys has resulted in the
almost precise replacement of the C-terminal SPRY domain
with a cyclophilin A (CypA) domain (Nisole et al., 2004; Sayah
et al., 2004). The resulting protein, TRIMCyp, potently inhibits
HIV-1 infection as a consequence of the apparently unique
ability of the HIV-1 capsid to bind to CypA.
The existence of numerous mammalian TRIM genes
encoding proteins with similarity to TRIM5 begs the question
of whether they are capable of inhibiting retrovirus infection
and, if not, what is special about the TRIM5 protein that enables
it to do so. Other TRIM proteins have been implicated in
defense against infection by retroviruses and other viruses, but
none has yet been shown to exhibit the potency and specificity
of TRIM5α (Chelbi-Alix et al., 1998; Maul and Everett, 1994;
Turelli et al., 2001; Yap et al., 2004, 2005). In this study, we
have begun to examine the antiretroviral potential of a
collection of human TRIM proteins, focusing primarily on
those most closely related to TRIM5α.
Results
To begin to address whether TRIM proteins might have a
role in antiretroviral defense, we performed a variety of assays
designed to uncover antiretroviral activities in human TRIM
proteins. TRIM proteins were selected for study based on close
sequence similarity to the known restriction factor, TRIM5α,
occurrence in the same cluster of TRIM genes on chromosome
11 as TRIM5α (TRIM6, TRIM21, TRIM22 and TRIM34) orpreviously reported activity against N-MLV or other viruses
(TRIM1, TRIM18, TRIM19). A variety of criteria were applied
to determine (1) whether the TRIM motif of each TRIM protein
had antiretroviral potential when targeted to an incoming
retrovirus by known capsid binding protein; (2) whether
siRNA-mediated depletion of, or expression of putative
dominant-negative versions of each TRIM protein could
enhance the infection sensitivity of human cells; (3) whether
overexpression of the TRIM genes in nonhuman cells could
inhibit retrovirus infection. We first examined wild-type or
mutant MLV and HIV-1 strains that are known or suspected to
be restricted in human cells. Subsequently, we examined a panel
of very diverse retroviruses including representatives that have,
or have not, colonized humans.
Examination of the anti-HIV-1 activity of various TRIM
domains fused to CypA
First, we determined whether the TRIM motif (consisting of
RING, B-box and coiled-coil domains) of each of the
aforementioned TRIM proteins intrinsically possessed the
ability to inhibit retrovirus infection when targeted to an
incoming capsid. To accomplish this, we took advantage of the
fact that a fusion protein that naturally occurs in owl monkeys,
TRIMCyp, contains a C-terminal CypA domain in place of the
usual SPRY domain (Nisole et al., 2004; Sayah et al., 2004).
The presence of the CypA domain targets TRIMCyp specifi-
cally to HIV-1 capsids through the well-characterized CypA:CA
interaction (Luban et al., 1993; Yoo et al., 1997). Therefore,
each of the human TRIM domains was fused in frame to the
intervening spacer peptide and CypA domain from the owl
monkey TRIMCyp protein in place of the existing owl monkey
TRIM5 domain. The details of the construction are outlined in
Fig. 1A, and the configuration was designed to recapitulate as
accurately as possible the configuration of the TRIM domain-
CypA fusion found in the owl monkey TRIMCyp protein. In
addition, we have previously shown that appending the C-
terminus of owl monkey TRIMCyp with a fluorescent protein
(CFP or GFP) does not measurably affect its ability to inhibit
HIV-1 infection (Perez-Caballero et al., 2005b). Thus, each of
the artificial TRIMCyp fusion proteins was also appended with
GFP to facilitate determination of the localization and
antiretroviral activity of the various TRIMCyp proteins.
Each of the TRIMCyp-GFP fusion proteins was expressed
in MDTF cells using retroviral vectors, and as can be seen in
Fig. 1B, there was some variation in expression level. To
ameliorate the potentially confounding effects of expression
level on restriction activity, we carried out subsequent studies
using cells that were either untreated or treated with sodium
butyrate. In each case, butyrate treatment increased the level of
TRIMCyp-GFP expression (Fig. 1B). The degree to which the
expression of each protein was increased upon sodium
butyrate treatment varied but, in most cases, allowed the
influence of expression level on restriction activity to be
assessed.
The ability of each TRIMCyp-GFP fusion protein to
inhibit HIV-1 infection was measured using pools of G418-
Fig. 1. Properties of various TRIMCyp fusion proteins. (A) Schematic representation of owl monkey TRIMCyp highlighting the junction between sequences encoding
TRIM5 and the retrotransposed CypA pseudogene. TRIM5 sequences were replaced by corresponding sequences from the indicated human TRIM genes. (B) Western
blot analysis, using an αGFP antibody, of the various TRIMCyp-GFP fusion proteins. Lysates of MDTF cells stably expressing the various TRIMCyp-GFP fusion
proteins, and either not treated (−) or treated for 24 h with sodium butyrate (+) were analyzed. The numbers above each pair of lanes designate the human TRIM
component of the fusion protein. ‘o5’ refers to the owl monkey TRIM5-based TRIMCyp-GFP fusion protein. (C) sensitivity of the various TRIMCyp-GFP-expressing
MDTF cell lines to infection by DsRed-expressing HIV-1 vectors packaged using a wild-type HIV-1 Gag-Pol expression vector or, one in which the CA sequences
have been replaced by those of SIVMAC (HIV(SIVCA)). The fraction of GFP+ cells that were also DsRed+ is plotted for each TRIMCyp-GFP fusion protein. ‘o5’
refers to the owl monkey TRIMCyp-GFP fusion protein, and (−) refers to MDTF cells not expressing any TRIMCyp-GFP fusion protein. (D) Same as C except that the
target cells were treated with sodium butyrate for 24 h prior to infection. (E) Subcellular localization of the various TRIMCyp-GFP fusion proteins, determined in
unmanipulated cells (upper row) or after 24 h of induction with sodium butyrate (lower row). Images represent single, deconvolved optical sections, and nuclei are
stained with DAPI (blue).
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LNCX2/TRIMCyp-GFP retroviral vectors. Cells were chal-
lenged with VSV-G pseudotyped HIV-1 vectors carrying a
DsRed reporter gene or, as a control, otherwise identical
vectors containing a chimeric Gag protein in which the CA
domain was from SIVMAC239 (HIV (SIVCA)). The percen-
tage of DsRed-positive cells in the GFP-positive cell
population was determined. As can be seen in Fig. 1C,
there was significant variation in the ability of the TRIMCyp
fusion proteins to block HIV-1 infection, but none was as
potent as the owl monkey TRIMCyp-GFP protein (designated
‘o5’ in Fig. 1). Surprisingly, even the TRIMCyp-GFP protein
based on human TRIM5 was less potent than owl monkey
TRIMCyp-GFP (Fig. 1C), although this may have been due
to its rather low level of expression (Fig. 1B).Among the other TRIMCyp-GFP proteins, those based on
TRIM1, TRIM6, TRIM18, TRIM21 and TRIM5 inhibited
HIV-1 infection by 4- to 12-fold while that based on TRIM34
had weak activity (∼2.5-fold inhibition) and those based on
TRIM19 and TRIM22 were almost inactive (<2-fold inhibi-
tion) (Fig. 1C). These results were only marginally affected
when the expression level of the TRIMCyp-GFP proteins was
increased by pretreating cells with sodium butyrate (Fig. 1D),
suggesting that expression level was not a major determinant
of restriction activity.
We also determined the subcellular localization of each
TRIMCyp-GFP fusion protein, with or without induction of
higher level expression by sodium butyrate. In some, but not
all, cases, increasing expression level had quite substantial
effects on protein localization (Fig. 1E). As we have
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protein exhibited both diffuse and punctate distributions with
the latter being favored under conditions of high expression
(Perez-Caballero et al., 2005b). Similarly, sodium butyrate
treatment led to a change in the localization of the TRIM1
and TRIM22-based TRIMCyp-GFP proteins from a diffuse
cytoplasmic distribution to obvious accumulations in aggre-
gates, or so-called ‘cytoplasmic bodies’. Curiously, in the
latter case, nuclear bodies were lost when expression levels
were enhanced. While the reasons for this are unclear, we
speculate that rapid formation of cytoplasmic aggregates
under conditions of high-level expression inhibits nuclear
import of TRIM22 and formation of nuclear bodies. With the
exceptions of TRIM19 and TRIM21, the other TRIMCyp-
GFP proteins formed cytoplasmic bodies and their localiza-
tion was less affected by increased expression level, although
we did note that the size and number of bodies were
sometimes affected by increasing expression level. For both
TRIM6 and TRIM34, the distribution of the Cyp-GFP
proteins was clearly asymmetric within the cytoplasm. Indeed
there was a tendency of small puncta to accumulate in a
single perinuclear cluster, perhaps suggesting some influence
of the cytoskeleton on their localization. Again, this
characteristic localization was lost upon induction of over-
expression with sodium butyrate. As expected, the fusion
protein based on TRIM19 (also known as PML) formed
nuclear bodies, although we also noted large cytoplasmic
aggregates in many cells. The TRIM21-based TRIMCyp-GFP
was unique in that its distribution remained entirely diffuse,
even upon induction of high-level expression by sodium
butyrate.
Notably, however, localization did not appear to be a
determinant of restriction activity. TRIMCyp-GFP proteins that
were diffuse or concentrated in cytoplasmic aggregates/bodies
could inhibit HIV-1 infection. Thus, as we and others have
previously concluded, cytoplasmic body formation is not
required for restriction activity and may simply be an artifact
of overexpression (Diaz-Griffero et al., in press; Perez-
Caballero et al., 2005a,b; Song et al., 2005a).
Restriction activity of authentic TRIM proteins against MLV
and HIV-1
Given that the TRIMCyp fusion proteins based on TRIM1,
5, 6, 18 21 and 34 were able to restrict HIV-1 infection, we next
tested whether the corresponding proteins that retained their
authentic C-terminal domains could inhibit infection by retro-
viruses that are known or suspected to be restricted in human
cells. Specifically, wild-type HIV-1 was tested along with two
CA mutants, namely G89V and G94D. The G89V CA mutant
lacks the ability to bind CypA (Saphire et al., 1999) and exhibits
reduced titer, specifically in human cells. However, it is unclear
whether this reduced infectivity is due to restriction by TRIM5α
(Towers et al., 2003; Yap et al., 2004). HIV-1 (G94D) also
exhibits reduced titer compared to WT HIV-1 in some human
target cells (e.g., HeLa and H9) but not in others (e.g., HOS and
Jurkat). Interestingly, the apparently restricted phenotypeconferred by G94D requires CypA:CA interaction but is not
mediated by human TRIM5α (Hatziioannou et al., 2005;
Sokolskaja et al., 2004).
Thus, because HIV-1 (G89V) and HIV-1 (G94D) are
apparently restricted in a possibly TRIM5α-independent
manner in human cells, they were good candidates to test
for restriction by the TRIM5α related proteins. N-MLV that
is restricted in human cells by TRIM5α, and B-MLV, which
is not, were included in these experiments as controls for
specific and nonspecific effects. We adopted several
strategies to determine whether candidate TRIM proteins
were capable of or responsible for restriction of these HIV-1
mutants. We first used siRNA-induced depletion of each of
the TRIM proteins that were able to restrict WT HIV-1 in
the context of TRIMCyp-GFP (TRIM1, 5, 6, 18, 21, 34) to
determine whether the endogenously expressed proteins were
responsible for apparent restriction of HIV-1 mutants in
human cells. Target cells consisted of TE671 cells, which
restrict N-MLV and HIV-1 (G89V), and HeLa cells, which
more weakly restrict N-MLV and HIV-1 (G89V), but exhibit
reduced sensitivity to HIV-1 (G94D).
To verify that each TRIM-specific siRNA was indeed
capable of depleting the TRIM proteins to which they were
targeted, each siRNA, or a control siRNA, was cotransfected
with plasmids expressing full-length TRIM proteins bearing
an amino-terminal HA epitope tag in HeLa cells. As can be
seen in Fig. 2A, all of the siRNAs profoundly reduced the
expression of the epitope tagged TRIM proteins, to virtually
undetectable levels. Next, we transfected TE671 or HeLa
cells with each siRNA and subsequently inoculated them
with N- and B-MLV, as well as wild-type and mutant HIV-1
vectors. As can be seen in Figs. 2B and C, depletion of
TRIM5 cells enhanced N-MLV titers, by approximately 30-
fold in TE671 cells and 5-fold in HeLa cells, such that they
approached those of B-MLV. Conversely, TRIM protein
depletion had no effect on B-MLV infection, which is not
thought to be restricted in human cells. Notably, none of the
siRNAs that inhibited TRIM protein expression had
significant effects on infection of TE671 or HeLa cells by
either wild-type HIV-1 or the G89V or G94D mutants (Figs.
2B and C). Similar results were obtained when multiple
TRIM proteins were depleted using pools of TRIM-specific
siRNAs (Supplementary Fig. 1). Thus, these data suggested
the apparent restriction of G89V and G94D mutant HIV-1 in
human cells was not due to the endogenous expression of
the TRIM proteins targeted here.
As an alternative approach to determine whether
endogenous TRIM proteins might be responsible for
restriction in human cells, we used an approach in which
truncated TRIM proteins lacking the C terminal SPRY
domain are over expressed in target cells. We have
previously shown that a truncated form of TRIM5 lacking
the SPRY domain (δSPRY) can completely abolish N-MLV
restriction in human cells, by sequestering the endogenous
full-length TRIM5α heteromultimers via interactions
mediated by the coiled-coil domain (Perez-Caballero et al.,
2005a). This approach is most successful in HeLa cells
Fig. 2. Effects of TRIM protein depletion by RNAi on the sensitivity of human cells to infection by MLV and HIV-1. (A) Western blot analysis of HA-tagged
TRIM protein expression following cotransfection of HeLa cells with LNCX-derived plasmids expressing the various HA-tagged TRIM proteins and either a
specific siRNA (+) or a control siRNA directed against luciferase (−). (B, C) Sensitivity of TE671 cells (B) or HeLa cells (C) to infection by N-MLV, B-MLV,
wild-type or mutant HIV-1 vectors, following transfection with siRNAs specific for the indicated TRIM proteins. Controls included cells that were transfected with
an siRNA that targeted luciferase (L) or were not transfected (−). The percentage of infected (GFP-positive) cells is plotted.
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TRIM proteins.
As can be seen in Fig. 3A, each of the truncated human
TRIM (δSPRY) proteins was expressed in human cells at
the same or higher levels than the protein derived from
human TRIM5. In each case, expression could be further
enhanced by pretreatment of cells with sodium butyrate. As
we have previously shown, overexpression of the TRIM5
(δSPRY) protein completely abolished N-MLV restriction
and increased titers to the same level as that of B-MLV
(Perez-Caballero et al., 2005a). However, as shown in Fig.
3B, both TRIM6 (δSPRY) and TRIM34 (δSPRY) exhibited
the same activity and almost completely abolished N-MLV
restriction, although TRIM6 (δSPRY) was marginally less
active than TRIM34 (δSPRY) and TRIM5 (δSPRY). In fact,
the truncated TRIM proteins were even more effective
inhibitors of restriction than were siRNAs, with TRIM5
(δSPRY) or TRIM34 (δSPRY) expression resulting incomplete restoration of N-MLV infectivity in HeLa cells
(Fig. 3B and Supplementary Fig. 2). Conversely, expression
of other TRIM (δSPRY) proteins had only slight effects on
N-MLV titer, with increases of 2-fold or less as compared to
unmodified HeLa cells.
While the ability of TRIM6 (δSPRY) and TRIM34
(δSPRY) expression to enhance N-MLV infection in human
cells was initially surprising, given that N-MLV restriction
therein is thought to be entirely due to TRIM5, it has
previously been shown that TRIM6 can form heteromulti-
mers with TRIM5 (Reymond et al., 2001). To test whether
this was also true of TRIM34, we used yeast two hybrid
assays. As can be seen in Table 1, TRIM5 fused to a GAL4
DNA binding domain efficiently formed homomultimers
with TRIM5. Notably, however, TRIM5 also formed
heteromultimers, albeit less efficiently, with both TRIM6
and TRIM34. Because of this finding and the fact that
siRNA-mediated depletion of TRIM5, but not TRIM6 or
Fig. 3. Effects of truncated TRIM protein overexpression on the sensitivity of human cells to infection by MLV and HIV-1. (A) Western blot analysis of HA-tagged
TRIM protein expression following transduction of HeLa cells with LNCX-derived vectors expressing the various HA-tagged TRIM proteins lacking the C-terminal
SPRY domain (δSPRY, see Materials and methods for details). Cells were harvested and analyzed with no pretreatment (−), or following pretreatment with sodium
butyrate (+). (B) Sensitivity of HeLa cells to infection by N-MLV, B-MLV, wild-type or mutant HIV-1 vectors when expressing each of the indicated TRIM(δSPRY)
proteins. Control HeLa cells were unmanipulated (−).
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overexpression of truncated versions of TRIM6 and
TRIM34 likely inhibits N-MLV restriction by sequestering
endogenous TRIM5 into inactive heteromultimers.
We next tested whether Hela cells that overexpressed the
TRIM (δSPRY) proteins exhibited altered sensitivity to the
wild-type or G89V or G94D mutant HIV-1 vectors. In
general, there was little or no effect on infection by these
two HIV-1 mutants (Fig. 3B), with the exception that
truncated forms of TRIM5 and TRIM34 modestly increased
the titer of HIV-1 (G89V) when cells were treated with
sodium butyrate to enhance expression of the truncated
proteins (Supplementary Fig. 2). Thus, these data suggested
that HIV-1 (G89V) may be weakly restricted in HeLa cells
by endogenous TRIM5, TRIM34 or an unknown protein
capable of forming heteromultimers with these two truncated
TRIM proteins.Table 1
Yeast two-hybrid analysis of TRIM protein heteromultimerization
GAL4 GAL4-TRIM5α
VP16 0.005 a 0.025
VP16-TRIM5 0.020 4.71
VP16-TRIM6 0.008 0.82
VP16-TRIM34 0.003 0.19
a Values represent β-galactosidase activity (given in OD590 units) in a pool of
Y190 yeast transformants expressing the indicated GAL4 DNA binding domain
and VP16 transcription activation domain TRIM fusion proteins.Anti-MLV and HIV-1 activity of full-length TRIM proteins
expressed in MDTF cells
As a further test of the antiretroviral potential of the panel of
TRIM proteins, each was stably expressed as a full-length, HA-
tagged protein in MDTF cells using LNCX-derived retroviral
vectors. As expected, there was some degree of variation in
expression level among the TRIM proteins (Fig. 4A). There-
fore, we tested restriction with and without sodium butyrate
induction, as before, to examine effects of expression level in
restriction activity. As can be seen in Fig. 4B, only TRIM5
significantly inhibited N-MLV infection in uninduced cells.
Marginal inhibition was also apparent in cells expressing
TRIM1, as has been previously reported (Yap et al., 2004). In
general, manipulation of TRIM protein expression level using
sodium butyrate had little effect on these results with the
exception that N-MLV inhibition by TRIM1 became more
dramatic upon treatment of target cells with sodium butyrate
(Supplementary Fig. 3), which clearly enhanced TRIM1
expression (Fig. 4A).
Inoculation of the panel of TRIM protein-expressing cells
with wild-type or G89Vor G94D mutant HIV-1 vectors did not
reveal any restriction activities among the intact TRIM proteins,
with one exception. Notably, infection by HIV-1 (G89V) was
modestly but specifically and significantly inhibited (3- to 4-
fold) by human TRIM5α (Fig. 4B). This phenotype was
predicted by our earlier studies which showed that G89V
mutant but not wild-type HIV-1 capsids can saturate N-MLV
Fig. 4. Effects of full-length TRIM protein expression on the sensitivity of nonrestricting murineMDTF cells to infection byMLVand HIV-1. (A)Western blot analysis
of HA-tagged TRIM protein expression following transduction of MDTF cells with LNCX-derived vectors expressing the various HA-tagged full-length TRIM
proteins. Cells were harvested and analyzed with no pretreatment (−), or following pretreatment with sodium butyrate (+). (B) Sensitivity of MDTF cells to infection
by N-MLV, B-MLV, wild-type or mutant HIV-1 vectors expressing each of the indicated full-length TRIM proteins.
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(Sokolskaja et al., 2006; Yap et al., 2004). However, we
obtained this result numerous times in separately derived pools
and clones of murine MDTF and feline CRFK cells (data not
shown and see below). Nonetheless, the degree of HIV-1
(G89V) restriction by human TRIM5α is clearly more modest
than that of N-MLV and suggests that recognition of incoming
HIV-1 (G89V) capsids by human TRIM5α and is quite
inefficient. Moreover, these data indicate that restriction
activities that are not readily apparent at endogenous levels of
TRIM protein expression can be revealed by exogenous
overexpression of TRIM proteins.
Antiretroviral potential of TRIM proteins against diverse
retroviruses
We next tested whether any of the aforementioned TRIM
proteins could inhibit infection by retroviruses other than
HIV-1 or MLV. Because several reporter viruses were
available only as nearly full-length lentiviral genomes, with
a GFP reporter gene placed in the Nef position, we slightly
altered the format of the restriction assay, because murine
MDTF cells do not support efficient reporter gene expression
due to incompatibility of the primate lentivirus Tat and
murine cyclinT1 proteins (Bieniasz et al., 1998; Garber et al.,
1998). Specifically, we generated feline CRFK cells expres-
sing each of the full-length, HA-tagged TRIM proteins by
transduction with LNCX-derived retroviral vectors and
selection of TRIM protein-expressing pools.We inoculated the pools of TRIM protein-expressing CRFK
cells with GFP-expressing reporter viruses based on the
genomes of HIV-2ROD, SIVMAC, SIVAGMTan, SIVAGMSab as
well as GFP-expressing EIAV, HTLV-I and prototypic foamy
virus (PFV) based vectors. With the exception of PFV, which
requires its own envelope to mediate assembly, the naturally
occurring envelope proteins were removed and the reporter
viruses/vectors were pseudotyped with VSV-G. As can be seen
in Fig. 5, most human TRIM proteins did not inhibit infection
by most retroviruses with the following exceptions: in
particular, HIV-2ROD infection was inhibited approximately 3-
to 5-fold by TRIM5α (‘5’ in Fig. 5) and marginally (<2-fold) by
TRIM34 and owl monkey TRIMCyp (‘34’ and ‘o5’ in Fig. 5).
Additionally, SIVMAC was inhibited 2-fold by TRIM5 and 3-
fold by TRIM34. Conversely, SIVAGMSab and SIVAGMTan
were unaffected by any human TRIM protein but SIVAGMTan
was inhibited 8-fold by owl monkey TRIMCyp (‘o5’, Fig. 5).
EIAV was inhibited 7- to 9-fold fold by TRIM5 and marginally
(<2-fold) by TRIM34. Thus, these results suggested that
TRIM34, which is one of the closest relatives of TRIM5,
might also modestly inhibit retroviral infection of human cells
in some instances and that TRIMCyp might also inhibit
SIVAGMTan infection of owl monkey cells.
Weak restriction of lentivirus infection by ectopically but not
endogenously expressed TRIM34
The aforementioned results were obtained using pooled
G418-resistant cells transduced with LNCX-derived vectors
Table 2
Restriction activity of ectopically expressed TRIM5 and TRIM34 in CRFK
clones
Virus Infection sensitivity of CRFK cell clones expressing a
TRIM5 TRIM34
HIV-1 (WT) 0.71 ± 0.17 0.94 ± 0.03
HIV-1(G89V) 0.22 ± 0.02 0.70 ± 0.05
HIV-2ROD 0.18 ± 0.03 0.48 ± 0.04
SIVMAC 0.51 ± 0.12 0.27 ± 0.02
EIAV 0.08 ± 0.01 0.58 ± 0.020
N-MLV 0.006 ± 0.001 1.27 ± 0.11
a Infection sensitivity is given relative to that of unmanipulated CRFK cells
which was arbitrarily set at a value of one. The values are given as a
mean ± standard deviation of 3 determinations of relative infection sensitivity of
TRIM expressing CRFK cells using virus doses that resulted in infection of 5 to
30% of the unmodified CRFK cells.
Fig. 5. Effects of full-length TRIM protein expression on the sensitivity of nonrestricting feline CRFK cells to infection by various retroviruses. CRFK cells stably
expressing each of the indicated full-length TRIM proteins were inoculated with GFP-expressing reporter viruses or vectors based on the genomes of HIV-1NL4-3,
HIV-2ROD, SIVMAC, SIVAGMSab, SIVAGMTan, EIAV, HTLV-I or PFV, as indicated ‘o5’ refers to owl monkey TRIMCyp and (−) refers to control CRFK cells. The
percentage of infected (GFP-positive) cells is plotted.
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TRIM proteins can be underestimated because a fraction of
the cells in the G418-resistant pool fail to express the
transduced TRIM protein and this contributes a background,
unrestricted level of infectivity (Perez-Caballero et al., 2005a).
This can make the discrimination of strong and weak
restriction by TRIM proteins somewhat difficult. To circum-
vent this problem, we used a previously described strategy in
which single cell clones expressing the TRIM proteins of
interest were derived. This approach ensures that close to
100% of the target cells actually express the TRIM protein
and, in cases where the TRIM protein is highly active,
reduces the ‘background’ level of infection. This enables the
degree of inhibition mediated by TRIM proteins to be more
accurately assessed (Perez-Caballero et al., 2005a). In this
instance, for comparative purposes, we derived single cell
clones of CRFK cells expressing HA-tagged human TRIM5
and TRIM34. Western blot analysis showed that the clones
expressed nearly identical levels of HA-TRIM5 or HA-
TRIM34 (data not shown).
As can be seen in Table 2, clones of CRFK cells expressing
human TRIM5 were only marginally less sensitive to wild-type
HIV-1 and SIVMAC as compared to unmodified CRFK cells.
Conversely, human TRIM5-expressing CRFK clones were 5-
fold less sensitive to HIV-2ROD infection and 10-fold less
sensitive to EIAV than unmodified CRFK cells. Relativelystrong inhibition of EIAV infection by human TRIM5 and
partial inhibition of HIV-2 and SIVMAC has been described
previously (Hatziioannou et al., 2004a,b; Stremlau et al.,
2004; Ylinen et al., 2005), and these findings are similar to
previous reports. Incidentally, human TRIM5-expressing
CRFK clones were also 5-fold less sensitive to HIV-1
(G89V) as compared to unmodified cells, consistent with
our findings in MDTF cells (Fig. 4). Moreover, as can be
seen in Table 2, CRFK clones expressing human TRIM34
also exhibited altered sensitivity to retrovirus infection.
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HIV-2ROD and EIAV and 4-fold less sensitive to SIVMAC.
However TRIM34 expression did not affect or only margin-
ally affected CRFK sensitivity to HIV-1 (WT), HIV-1 (G89V)
or N-MLV. Thus, human TRIM34 is intrinsically capable of
inhibiting infection by some retroviruses, albeit significantly
less potently than TRIM5α.
Next, we used siRNA-mediated depletion to test whether
TRIM5 and or TRIM34 endogenously expressed by human
TE671 or HeLa cells could affect infection by HIV-2ROD,
SIVMAC or EIAV. In fact, only TRIM5 depletion enhanced HIV-
2ROD (4-fold) and EIAV (5-fold) infection in TE671 cells (Fig.
6A), as previously reported (Hatziioannou et al., 2004a,b;
Ylinen et al., 2005). Depletion of TRIM5 had little effect on
SIVMAC infection. Surprisingly, these effects were only evident
in TE671 cells and not in HeLa cells (Fig. 6B). We presume that
this is because HeLa cells express less TRIM5 than TE671 cells,
or that TRIM5 is less active therein. This notion is consistent
with the observation that N-MLV is clearly more strongly
restricted in TE671 than in HeLa cells (Fig. 2). Notably,
depletion of endogenous TRIM34 had no effect on HIV-2ROD,
SIVMAC, or EIAV infection, either in TE671 or in HeLa cells
(Figs. 6A, B). Previous reports have indicated that TRIM34
mRNA expression is inducible by interferon-α in HeLa cellsFig. 6. Effects of endogenously expressed TRIM5 and TRIM34 on infection of
human TE671 and HeLa cells by HIV-2ROD, SIVMAC and EIAV. Sensitivity of
TE671 cells (A) or HeLa cells (B) to infection by HIV-2ROD, SIVMAC and EIAV,
following transfection with siRNAs specific for TRIM5 or TRIM34 proteins, or
luciferase (L) as a control. The percentage of infected (GFP-positive) cells is
plotted.(Orimo et al., 2000). Nonetheless, even when cells were treated
with interferon-α, as described previously (Orimo et al., 2000),
in neither HeLa nor TE671 cells did TRIM34 depletion affect
infection by any of the aforementioned viruses (data not
shown). We conclude from these results that the weak
antiretroviral activity of TRIM34 against HIV-2, SIVMAC, or
EIAV is likely only measurable under conditions of ectopic
expression, which is probably higher than occurs in TE671 or
HeLa cells.
Restriction of SIVAGMTan by endogeneously expressed owl
monkey TRIMCyp
We also tested whether SIVAGMTan infection was blocked
by the levels of TRIMCyp that are found endogenously in
owl monkey cells. We first tested whether SIVAGMTan was
indeed restricted in owl monkey cells by inoculating OMK
cells with a fixed dose of the SIVAGMTan reporter virus in the
presence of increasing amounts of noninfectious SIVAGMTan
or HIV-1 virus-like particles (VLPs) that lacked viral genomic
RNA. As can be seen in Fig. 7A, the noninfectious VLPs
enhanced SIVAGMTan reporter virus infection by up to 100-
fold. Since it is known that HIV-1 VLPs can abolish
resistance to HIV-1 infection by saturating owl monkey
TRIMCyp (Nisole et al., 2004; Sayah et al., 2004; Towers et
al., 2003), this result suggested that SIVAGMTan is restricted
by the same factor. To confirm this notion, OMK cells were
inoculated with the SIVAGMTan reporter virus in the presence
(or absence) of CsA, which abolishes the activity of
TRIMCyp by competitively inhibiting interaction between
TRIMCyp and incoming capsids. As can be seen in Fig. 7B,
CsA treatment of OMK cells increased their sensitivity to
SIVAGMTan by almost 100-fold. Thus the results shown in
Fig. 7 indicate that endogenous levels of TRIMCyp are
capable of strongly inhibiting infection by SIVAGMTan.
Discussion
Previous studies have shown that TRIM5α is capable of
inhibiting infection by a wide array of retroviruses, with large
variations in antiretroviral potency depending on the parti-
cular retrovirus that is targeted and the species from which the
TRIM5α protein is obtained (Hatziioannou et al., 2004a,b;
Keckesova et al., 2004; Perron et al., 2004; Stremlau et al.,
2004; Yap et al., 2004). In this study, we tested whether a
selected group of additional human TRIM proteins could
exhibit inhibitory activity against a range of retroviruses.
Reasoning that TRIM proteins most closely related to
TRIM5α were the most likely candidates for novel restriction
activities, the TRIM proteins were selected on the basis of
whether they were homologous to TRIM5α, were part of a
cluster of TRIM genes on human chromosome 11, or have
previously been shown to exhibit antiviral activity. We found
that several of the TRIM proteins tested have the potential to
prevent retroviral infection because they could exhibit
reasonable degrees of inhibition when targeted to an incoming
HIV-1 capsid (by fusion to CypA). While most authentic,
Fig. 7. TRIMCyp endogenously expressed by owl monkey OMK cells potently
restricts SIVAGMTan infection. (A) Effects of noninfectious SIVAGMTan and
HIV-1 VLPs on infection of OMK cells. The OMK cells were inoculated with a
fixed dose of a GFP-expressing SIVAGMTan reporter virus. The percentage of
infected (GFP-positive) cells is plotted as a function of the dose of
simultaneously added noninfectious SIVAGMTan and HIV-1 VLPs. (B) CsA
inhibits SIVAGMTan restriction in OMK cells. The OMK cells were inoculated
with an increasing dose of a GFP-expressing SIVAGMTan reporter virus, in the
presence or absence of 5 μM CsA, as indicated.
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activity, presumably because they fail to recognize the
retroviruses tested, we confirmed previous findings that
human TRIM5 can exhibit broad antiretroviral activity, and
that human TRIM1 can inhibit N-MLV (Hatziioannou et al.,
2004a,b; Keckesova et al., 2004; Perron et al., 2004; Yap et
al., 2004). In addition, we found that human TRIM5 can
weakly but specifically inhibit an HIV-1 carrying a capsid
mutation in the CypA binding loop (G89V), that human
TRIM34 could exhibit weak antiretroviral activity against
certain lentiviruses (HIV-2ROD, SIVMAC and EIAV). Finally,
we found that owl monkey TRIMCyp strongly restricts the
AGM lentivirus SIVAGMTan.
Aside from the findings of novel restriction activities, the
results presented herein do highlight some experimental
difficulties in studying retrovirus restriction by TRIM
proteins. In some cases, restriction was only evident when
the TRIM proteins were ectopically expressed. For example,
TRIM1 inhibition of N-MLV and TRIM34 inhibition of
lentiviruses was observed when the TRIM proteins were
expressed in MDTF or CRFK cells, but siRNA induced
depletion of TRIM1 or TRIM34 in human HeLa or TE671
cells did not affect sensitivity to N-MLV or lentivirus
infection. It is possible that TRIM34 is simply not expressedin the cell lines that were tested or is expressed at levels that
are too low to recapitulate the modest inhibitory activity
exhibited in the engineered TRIM1 or TRIM34-expressing
CRFK cell lines. In addition, human cell lines clearly vary in
level of TRIM5-attributable restriction that can be detected.
For example, in TE671 cells, restriction of HIV-2, and
particularly EIAV, can be convincingly demonstrated using
siRNA based strategies, while in HeLa cells, TRIM5
knockdown had virtually no effect. Determining whether
novel TRIM protein-based restriction activities have relevance
in vivo will obviously, therefore, be complicated.
These limitations notwithstanding, we were able to show
novel and specific antiretroviral activities among TRIM
proteins. A surprising finding was that SIVAGMTan was
very potently inhibited by owl monkey TRIMCyp. In this
case, inhibition was clearly not due to TRIMCyp over-
expression because SIVAGMTan was restricted in OMK cells
in a CsA-reversible manner. This finding strongly suggests
that the SIVAGMTan capsid has at least some affinity for
CypA, which is unexpected. Indeed, previous work has
shown that SIVAGM strains, albeit from different SIVAGM
subspecies do not package CypA into virions (Braaten et al.,
1996). The significance of this observation is difficult to
determine, since lentiviruses appear to be absent from new
world primates. However, the fact that a retrovirus other than
HIV-1 is sensitive to owl monkey TRIMCyp restriction makes
more plausible the notion that this unique restriction factor
was evolutionarily selected in owl monkeys to confer
resistance to some ancient retrovirus (or other virus) whose
capsid exhibited CypA binding activity.
At this point, it is difficult to know the biological
significance of weak antiretroviral activity that was observed
in the context of some ectopically expressed human TRIM
genes (e.g., TRIM1, TRIM34). However, it is possible that
weakly restricting TRIM genes could influence and partly
constrain the spectrum of sequences that are explored by
retroviruses during natural infections. Alternatively, restriction
activities that are weak or absent when entry is mediated by
the VSV-G envelope protein used in these studies might be
accentuated when incoming capsids are delivered to a
particular location in the cell. Indeed, sensitivity to the
restriction activity referred to as Lv2 is influenced by both
envelope and capsid (Marchant et al., 2005; Reuter et al.,
2005; Schmitz et al., 2004). Finally, it is reasonable to think
that potent restriction activities were selected (by retroviral
epidemics) from weak TRIM gene restriction activities that
preexist in a given species. Indeed, TRIM5α likely arose as a
result of duplication of genes at locus that also contains a
weak restrictor, i.e., TRIM34. Sporadic occurrences of potent
antiretroviral activity (e.g., TRIMCyp on SIVAGMTan and
HIV-1 and even rhesus TRIM5 on HIV-1) that are uncovered
in the laboratory are probably the indirect and accidental
consequence of distant evolutionary events. While these
instances of strong restriction could recapitulate the char-
acteristics of past virus–host interactions, it is also possible
that reciprocal evolutionary pressure exerted on TRIM genes
and retroviruses could be far more subtle and complex.
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Construction of a panel of human TRIM protein expression
vectors
cDNAs encoding full-length versions of several members of
TRIM protein family, including TRIM1, TRIM6, TRIM18,
TRIM19, TRIM21, TRIM22, TRIM34, were amplified using
PCR from human placenta cDNA (Clontech) using the primers
corresponding to the 5′ and 3′ end of the coding sequences and
appended with sequences encoding XhoI restriction site at 5′
end and SalI at 3′ end. The PCR products were subcloned into
the retroviral expression vector pLNCX2 (Clontech) which was
modified such that the expressed protein encoded an HA
epitope tagged at its amino-terminus. Similar vectors, encoding
HA-tagged, but truncated forms of each TRIM protein, that
lacked the carboxy-terminal SPRY domain, were also con-
structed. In this case, the panel of full-length TRIM expression
vectors described above were used as templates for PCR
amplification using reverse primers targeted to the 3′ end of
these corresponding coiled-coil domains (at amino acid residue
483 for TRIM1, residue 298 for TRIM5, residue 300 for
TRIM6, residue 483 for TRIM18, residue 582 for TRIM19,
residue 286 for TRIM21, residue 300 for TRIM22 and residue
300 for TRIM34) appended with a stop codon (TAG) and a SalI
site. To construct the panel of TRIMCyp-GFP fusion proteins,
each TRIM domain was amplified using reverse primers
targeting the 3′ end of each coiled-coil domain, without
appending a stop-codon, but instead appending sequences
encoding a NotI restriction site. The PCR products, after
digestion with XhoI and NotI, were fused in-frame to a CypA-
GFP cassette in pLNCX2/CypA-GFP, which was constructed as
follows: A DNA fragment encompassing a 3′ fragment of Owl
monkey TRIMCyp, comprising the CypA domain as well as the
spacer peptide that naturally exists between the TRIM5 and
CypA domains in Owl monkey TRIMCyp (Nisole et al., 2004;
Sayah et al., 2004), was amplified using a 5′ primer that
encoded a NotI site underlying three Ala residues in the spacer
peptide and a 3′ CypA primer appended sequences derived from
the 5′ end of GFP. This was linked to a GFP encoding fragment
via PCR-mediated recombination so that the amplified CypA-
GFP fusion insert included NotI and SalI restriction sites at 5′
and 3′ ends respectively. This DNA fragment was inserted into
LNCX2 (Clontech) to generate pLNCX2/CypA-GFP. This
plasmid was then used to generate the panel of TRIMCyp-
GFP expression vectors, by inserting the various TRIM motifs
lacking the SPRY domain described above.
Cell lines, viruses and vectors
Adherent cell lines from human (HeLa, TE671, 293T), mouse
(Mus Dunni tail fibroblast, MDTF), cat (CFRK) and owl
monkey (OMK) were grown in DMEM/10%FCS/antibiotics. To
generate cell lines expressing the various TRIM proteins, 293T
cells were transfected with pLNCX2-based retroviral vector
containing the full-length versions, truncated, or Cyp-GFP-
fused TRIM proteins, along with MLV Gag-Pol and VSV-Gexpression plasmids. Virus stocks produced by these cells were
used to transduce MDTF and/or CRFK cells (for the full-length
and/or GFP-fused TRIM proteins) or HeLa cells (truncated
TRIM proteins). The transduced cells were selected in the
presence of 1 mg/ml G418 and used as a pool of target cells to
test sensitivity to retrovirus infection (see below).
Reporter viruses and vectors were based on the genomes
of MLV, HIV-1NL4-3, HIV-2ROD, SIVMAC, SIVAGMSab,
SIVAGMTan, EIAV, HTLV-I or prototypic foamy virus PFV,
and have been described previously (Bainbridge et al., 2001;
Bock et al., 2000; Cowan et al., 2002; Derse et al., 2001;
Hatziioannou et al., 2003; Meiering et al., 2000; Mitropha-
nous et al., 1999; Reuter et al., 2005). All expressed a GFP
reporter gene. The exception to this was an HIV-1 vector
pHR-SIN-CSW that was engineered to express DsRed for
experiments in which target cells expressed TRIMCyp-GFP
proteins. All virus/vector stocks were generated by transient
transfection of 293T cells using polyethyleneimine and were
pseudotyped with the VSV-G envelope protein, with the
exception of PFV, which requires expression of the PFV
envelope protein for efficient assembly/release.
Infection assays
Control and TRIM protein-expressing cells were seeded in
24-well plates and inoculated with GFP reporter viruses (for
MDTF, CRFK or Hela cells expressing full-length and truncated
TRIM proteins) or DsRed reporter viruses (for MDTF cells
expressing the Cyp-GFP-fused TRIM proteins) in the presence
of 5 μg/ml polybrene. For some experiments, indicated in the
text, cells were treated with 5 mM sodium butyrate 1 day prior
to infection, to increase the expression of the transduced TRIMs
proteins. Two days after inoculation with reporter viruses,
FACS analysis was carried out using Guava EasyCyte
instrument (Guava Technologies). For cells expressing the
Cyp-GFP fused TRIM proteins that were challenged with
DsRed reporter viruses, GFP-positive cells were gated and the
percentage of DsRed+GFP+ as compared to the total GFP+
population was taken as the measure of sensitivity to infection.
RNAi
Human HeLa and TE671 cells were mock transfected or
transfected with 60 pmol of each TRIM-specific RNA duplex
(SMART pool Dharmacon) or a control firefly luciferase duplex
using Oligofectamine (Invitrogen) according to manufacturers
instructions and replated 24 h later. Forty-eight hours after
transfection, cells were inoculated with GFP reporter viruses
followed by FACS analysis 2 days later. In some experiments,
where multiple siRNAs were mixed, 15 pmol of each TRIM-
specific siRNA was used.
Western blot analysis
Cell suspensions were normalized for cell number and
aliquots containing 5 × 103 cells were lysed directly in SDS
sample buffer, separated on SDS-PAGE gels and transferred to
407F. Zhang et al. / Virology 353 (2006) 396–409nitrocellulose membranes. Due to the very high expression level
of full-length, truncated and CypA-GFP fused versions of
TRIM19, extracts were diluted 5-fold such that only 1 × 103
cells were loaded per lane. The blots were probed with a mouse
α-HA antibody (Covance Inc.) or α-GFP antibody (Roche) and
a peroxidase conjugated secondary antibody and were devel-
oped with chemiluminescent detection reagents (Pierce).
Microscopy
MDTF cells expressing each of the TRIMCyp-GFP fusion
proteins were fixed with paraformaldehyde, stained with DAPI
and subjected to deconvolution microscopy using a Deltavision
microscope (Applied Precision). Images were acquired and
processed as previously described (Martin-Serrano et al., 2005).
Yeast two-hybrid assays
A bait plasmid expressing a GAL4-huTRIM5α fusion
protein was generated by insertion of huTRIM5α coding
sequences into pGBKT7 (Clontech). Yeast Y190 cells were
transformed with pGBKT7/huTRIM5α and pVP16/HA
(Bogerd et al., 1993) derivatives expressing the various TRIM
proteins. Interactions were measured using a β-galactosidase
reporter assay, as previously described (Bogerd et al., 1993;
Martin-Serrano et al., 2001).
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